patients with progressive/relapsed solid tumors who failed first line therapy , will be
treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation
low dose cyclophosphamide will be started .
patients on trial will submit tissue and blood tests for whole exome an immune genomic
signature. patients will also undergo repeated immunophenotype as part of follow up.